IGNITE International Brands, Ltd. (CSE:BILZ, OTCQX: BILZF) (“IGNITE” or the “Company”), a global consumer packaged goods brand, announced today that Greg Gilpin-Payne of International Stem Cell Enterprises and Darren Schwartz of Choice Management Corp. were elected to its board of directors.


Ignite International Brands, Ltd. (PRNewsfoto/Ignite International Brands, Lt)


Mr. Gilpin-Payne controls Vulcan Enterprises SKN, Ltd., Veritas Investments Ltd., and International Investments Inc., all of whom are significant shareholders of IGNITE.

“We are pleased to welcome Greg and Darren as new independent directors to IGNITE’s board,” said Lester Lee, IGNITE’s President.  “The addition of these individuals complements our board of directors’ skills and experiences, and we are confident they will provide valuable perspectives as we continue to execute our strategy, drive profitability and enhance value for all of IGNITE’s shareholders. We look forward to their contributions and are excited they chose IGNITE.”

The Annual General Meeting (AGM) of IGNITE took place via telephone on July 10, 2020 under special arrangements due to the COVID-19 pandemic. Shareholders representing approximately 243,264,150 shares and votes were represented at the meeting by proxy.

In addition, IGNITE’s shareholders voted in favour of increasing the size of the board to six directors, thereby in addition to Mr. Gilpin-Payne and Mr. Schwartz, shareholders also re-elected IGNITE’s existing four directors, namely, Dan Bilzerian, Lu Galasso, Tom Kofman and Lester Lee.  Lastly Shareholders also re-appointed Davidson & Company LLP as the auditors of IGNITE for the year ended December 31, 2020 and authorized IGNITE’s board to fix their renumeration.

ABOUT IGNITE

IGNITE is a global consumer products company operating in the premium segment of the market. Founded by Dan Bilzerian, the Company’s ‘quality-first’ approach is fundamental to everything IGNITE does. Originally operating in the cannabis and hemp-derived cannabidiol (CBD) wellness space, IGNITE was able to establish a high degree of brand awareness. IGNITE product categories now include a full line of CBD oil tinctures, CBD topicals, CBD pet products and CBD vape devices, produced by various partners and sold through select distributors, brick and mortar retailers, and online through the Company’s website, ignite.co. The IGNITE THC product line, which was launched subsequent to the CBD product line, incorporates quality, locally-sourced cannabis products.

Since the launching of its THC and CBD products, the Company has expanded into the beverage space, launching a full line of functional performance-enhancing drinks. The IGNITE beverage line currently consists of PH-alkaline balanced water, the ZRO line of premium performance drinks, and a gluten-free, seven-time distilled vodka. IGNITE beverages will be distributed nationally within the United States and available to purchase on the IGNITE beverages website, IgniteBeverages.co.

IGNITE is a socially responsible company and is committed to using its marketing and brand power as a positive catalyst for health and wellbeing. The IGNITE management team believes that socially-responsible actions have a positive impact on the Company, its employees and its shareholders.

Shares of IGNITE are listed on the Canadian Securities Exchange (CSE) under the symbol “BILZ” and quoted in the United States on the OTCQX under the symbol “BILZF”.

Further information on IGNITE can be found on the Company’s website at ignite.co.

For further information, please contact:
Linda K. Menzel, General Counsel
Tel: 310-867-3859
Email: linda.menzel@ignite.co
7074676

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ignite-announces-two-new-appointments-to-board-of-directors-and-results-of-2020-annual-general-meeting-301092756.html

SOURCE IGNITE International Brands, Ltd.

PR Newswire
July 14, 2020 – 3:03 AM PDT
News by QuoteMedia

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less